US Edition
News from MedCity News
If you want to know if MedCity News is credible or reliable, look no further. We rank MedCity News as High factuality. Find out more about our methodology here.
Media Bias Ratings
Average Bias Rating:
Center
Center
byAd Fontes MediaCenter
byMedia Bias/Fact CheckDo you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top MedCity News News
Donald Trump · United StatesMedCity News Editor in Chief Arundhati Parmar and Samir Batra, managing partner of Health Innovation Pitch, also discussed whether bitcoin would play a greater role in healthcare deals and the Trump administration’s mixed messages on autism and Tylenol. The post Debunked Episode 20: A Look at H-1B Visas in Healthcare, M&A Deals for Bitcoin and More appeared first on MedCity News.See the Story
Debunked Episode 20: A Look at H-1B Visas in Healthcare, M&A Deals for Bitcoin and More
50% Left coverage: 6 sources
WegovySkye Bioscience Inc. (NASDAQ:SKYE) stock sank on Monday after the company released topline data from its 26-week Phase 2a CBeyond proof-of-concept study of nimacimab. The nimacimab monotherapy arm did not achieve the primary endpoint of weight loss compared to placebo (-1.52% vs. -0.26 for placebo, mITT). Preliminary pharmacokinetic analysis showed lower than expected drug exposure of nimacimab, supporting evaluation of higher dosing. Also Read:…See the Story
Skye Bioscience's Investigational Drug Disappoints As Monotherapy For Weight Loss - Skye Bioscience (NASDAQ:SKYE)
80% Center coverage: 5 sources
FDA · United StatesThe FDA will provide faster regulatory review of generic drugs that are tested in and manufactured in the U.S. using domestically sourced active pharmaceutical ingredients. This FDA pilot program is part of a broader Trump administration strategy to reshore pharmaceutical production. The post FDA Pilot Program Creates New Path for Faster Regulatory Review of Generic Drugs appeared first on MedCity News.See the Story
FDA Pilot Program Creates New Path for Faster Regulatory Review of Generic Drugs
100% Center coverage: 2 sources
